Novo Nordisk is positioning itself as a long‑term leader across multiple obesity segments rather than relying on a single ...

The most notable strategic choice is prioritising myasthenia gravis (MG) and Sjögren's disease as lead indications while ...

Secondary US filings for Bayer assets cannot be relied on again to face future patent cliffs, demanding focus on early-stage ...

BD (Becton, Dickinson and Company) has announced a $110m investment to expand its production of prefillable syringes in the ...

The company will prioritise investment for in-house innovation over large M&A deals, bucking the trend across pharma.

The company is embracing AI integration throughout drug development, aiming to improve efficiency and drive portfolio ...

Full pipelines and rising revenues lead rare disease biotechs to restyle themselves as more mature, global biopharma ...

The request comes after a two-year review into reported links between GLP-1RAs and psychiatric adverse events.

Ionis is hoping to gain approval of Trygolza in severe hypertriglyceridemia which could set to to generate $2bn in sales.

Fortress Biotech has announced that its subsidiary, Cyprium Therapeutics, received US FDA approval for Zycubo for the ...

Dual-payload ADCs are gaining traction, offering opportunities to overcome the tumour heterogeneity and resistance challenges faced by conventional ADCs.